NantHealth Announces Commercial Availability of GPS Cancer™ and Launch of GPS Cancer Browser on a Secure Mobile Platform at the 2016 American Society of Clinical Oncology Annual Meeting

GPS Cancer combines the power of quantitative proteomics with genomics and transcriptomics to understand the "molecular fingerprint" of a cancer patient's tumor enabling personalized treatment options.

First cancer test to better inform chemotherapy choice with quantitative measurement of known drug resistance and chemo sensitivity protein biomarkers present in patient's cancer cells

Informed clinical decision support for taxanes, platinum and vinca alkaloids, the backbone of chemotherapy

CHICAGO, IL. AND CULVER CITY, CA. – June 3, 2016 –NantHealth, Inc. (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, announced today the commercial availability of Genomic Proteomic Spectrometry Cancer, or GPS Cancer™, a unique, comprehensive molecular test and decision support solution that measures the proteins present in the patient's tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.

GPS Cancer™ integrates targeted quantitative proteomics with whole genome (DNA) and whole transcriptome (RNA) sequencing, and a knowledge database containing hundreds of oncogenes and approximately 1,500 cellular pathways to identify genomic and proteomic alterations—from DNA to RNA to protein— targeting proteins with high clinical relevance to each person’s tumor and providing oncologists with a detailed molecular profile of a patient’s cancer to inform personalized treatment strategies.

With the capability to measure at a quantitative level, proteins which have known clinical significance relating to activity or resistance to chemotherapy, monoclonal antibody therapy (mAb), hormonal therapy, small molecule targeted therapy and checkpoint inhibitors, GPS Cancer™ is the most comprehensive molecular profiling solution of a patient's tumor tissue. Combined with whole genome and transcriptomic analysis, this test provides informed clinical decision support, arming the physician with insight into the patient’s response and resistance to particular therapeutics before treatment begins. This valuable information is available within 21 days of receipt of the tissue, thus enabling clinical utility.

 NantHealth will be exhibiting GPS Cancer™ and its other solutions for cancer care at ASCO booth #12135 from June 3-June 7, 2016. 

GPS Cancer™ results are available to doctors in an easy-to-read report or accessible through the GPS Cancer™ Genome Browser, a mobile application available on smartphones including the BlackBerry Priv.‎ The GPS Cancer Genome Browser is the first app enabling a physician and molecular scientists to browse the patient's whole genome down to a single base pair and provide visual insight into genomic alterations coupled to relevant data about that alteration.

GPS Cancer™ testing is conducted in the CLIA-certified and CAP-accredited laboratory of NantOmics, and is an enabler for the Cancer Breakthroughs 2020, the world’s most comprehensive cancer care collaborative seeking to accelerate the potential of combination immunotherapy as the next-generation standard of care in cancer patients.

"2016 has already been a banner year for NantHealth. On the heels of going public, today we’re announcing the commercial availability of GPS Cancer™ as well as the launch of GPS Cancer Genome Browser at one of the most significant oncology events worldwide at ASCO. The ability to bring next-generation cancer treatments to patients marks a significant milestone in the war against cancer," said Dr. Patrick Soon-Shiong, Founder and CEO of NantHealth. "While genomics has undoubtedly advanced our ability to treat cancer, gene panels have only given us a partial picture and only look at a fraction of the genome.  We have leapfrogged from genomics to the era of clinically relevant proteomics with this comprehensive integration of DNA, RNA, and quantitative protein analysis in a single molecular test—GPS Cancer™. Coupled with robust predictive analytics, this 21st century molecular profile offers clinicians and patients a powerful tool in fighting cancer at point of care and before treatment begins."

“Moreover, GPS Cancer™ is an enabler for facilitating the goals of the Cancer Breakthroughs 2020, the nation's most comprehensive cancer care initiative with the ambitious goal of creating a cancer vaccine by 2020, Dr. Soon-Shiong added, "GPS Cancer™ may accelerate efforts to bring novel combinations of therapeutic agents to cancer patients by providing the molecular fingerprinting foundation necessary to help identify patients eligible for QUILT, Quantitative Integrative Lifelong Trials. These clinical trials, which are at the heart of Cancer Breakthroughs 2020, are aimed to accelerate the potential of immunotherapy as the new standard of care for cancer patients by harnessing the power of the immune system to fight this disease.”‎ 

Today, many tests employ limited gene panels of 10-400 genes and a reference genome against which a patient’s tumor DNA is compared to identify alteration. GPS Cancer™ sequences the whole genome of 20,000+ genes and 3 billion base pairs and matches against the patient’s normal DNA, providing oncologists with an expansive view of alterations to inform personalized treatment strategies specific for that patient. GPS Cancer™ extends from genomics to proteomics not only through analysis of RNA but also provides quantitative proteomics through mass spectrometry to measure the amounts of clinically relevant proteins that are the targets of or essential for various therapeutics. This clinically relevant information helps oncologists to better understand how patients may potentially respond to chemotherapies, targeted therapies, and immunotherapies.

"GPS represents the new standard by which all complex molecular testing on tumors will be compared, there is no other CAP/CLIA approved genomic offering that come close to this level of sophistication and clinical utility," says Leonard Sender, MD, Medical Director of the Hyundai Cancer Institute at Children’s Hospital Orange County (CHOC Children’s).

“As a community oncologist, I couldn’t be more excited to have GPS Cancer available for my patients, particularly those with more difficult cases. I treat my patients like my family, and as such, I want them to have the best,” says Sibel Blau, MD, Northwest Medical Specialties and Rainier Hematology Oncology. “The unparalleled comprehensiveness of this test helps assure that we leave no stone unturned for our patients.”

“Using the NantOmics clinical quantitative proteomics test provides me a deeper understanding of the biology of my patient’s tumors which has helped me make better treatment decisions,” says Steven W. Mamus, MD, Medical Director, Oncology/Hematology, Cancer Center of Sarasota-Manatee.

 “At Indiana University Health, we aim to identify innovative therapeutic options for metastatic cancer patients through the use of cutting-edge precision medicine technologies. GPS Cancer with its combination of genomic and proteomic profiling has revealed numerous opportunities for treatment, providing actionable results for the majority of our patients,” says Milan Radovich, PhD, Co-director of the Indiana University Health Precision Genomics Program.   

The payer community has acknowledged the potential of GPS to improve outcomes by offering coverage for the test. In January 2016, Independence Blue Cross became the first major insurer to offer reimbursement for GPS Cancer for its members. In May 2016, NantHealth expanded coverage of GPS Cancer nationwide. These organizations include Bank of America, Sanford Health, and Phoenix Children’s Hospital, which became the nation’s first self-insured employers to cover next-generation whole genome sequencing for various cancers, helping their employees—and their families—to gain better insight and treatment strategies in optimizing cancer therapy. In addition, Sanford Health Plan, an NCQA-accredited regional health plan in the Dakotas, became the second commercial insurer to offer coverage for GPS Cancer. Read more HERE

“Bank of America provides coverage for about 500,000 employees and their families and for the past five years has worked closely with NantHealth to explore innovative methods for improving health & wellness for their associates,” said Jim Huffman, senior vice president, head of US Health and Wellness Benefits, Bank of America. “We are doing our part to address an issue that affects the lives of our employees, our customers and clients, and the people in the communities we serve around the world. We are committed to providing the most advanced cancer care to our employees and the Cancer Breakthroughs 2020 initiative with its national footprint of oncologists practicing cutting edge medicine is a valuable resource we will now be able to offer to our 500,000 beneficiaries.”

“To that end, I am proud to say that Bank of America is one of the first large, self-insured employers to partner with Dr. Soon-Shiong ‎and NantHealth to adopt GPS Cancer as the most comprehensive test to help inform the oncologists taking care of its employees and families diagnosed with cancer,” continued Huffman. “We believe this test provides an opportunity for our associates to address the question many patients may ask of their prescribing clinician: 'Doctor, what further information do you have from my tissue samples that will provide more information about the probabilities of effectiveness of the treatment being prescribed before I begin my therapy?”

“At Sanford Health, we are dedicated to offering our employees affordable and accessible high-quality care. Not only is GPS Cancer testing a novel approach to cancer care, it offers our employees – and their families – the best possible coverage for receiving improved cancer treatment options,” said Rich Adcock, Chief Innovation Officer, Sanford Health. “As one of the founding members of the National Immunotherapy Coalition and Pediatrics Consortium, we are committed to the Cancer Breakthroughs 2020 program and its initiatives to win the war on cancer.”

“As a hospital dedicated to providing the most advanced care, it only makes sense that we would cover the innovative GPS Cancer Testing for our employees and their families under our insurance plan,” said Robert Meyer, President and CEO, Phoenix Children’s Hospital. “We understand the power of personalized medicine and want to provide it to our patients and our employees.”

Cautionary Note Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the capabilities and anticipated utility of our GPS Cancer, including predicting patient response and resistance to therapeutics, enabling diagnoses by physicians and accelerating efforts to bring novel combinations of therapeutic agents to cancer patients, as well as our contribution to the Cancer 2020 initiative. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results. Factors that may cause future results to differ materially from management’s current expectations include, among other things, that GPS Cancer may not perform as anticipated, that sufficient physicians may not adopt GPS Cancer to assist their diagnoses or that healthcare payers may not provide reimbursement for GPS Cancer as expected.  Our business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of our products; our ability to successfully launch new products and applications; competition; our sales, marketing and distribution capabilities; our planned sales, marketing, and research and development activities; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting our business and operating results can be found in our existing and future filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements except as may be required by law. 

About GPS Cancer™

GPS Cancer™ is a unique, comprehensive test available through NantHealth. GPS Cancer integrates whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics through mass spectrometry, providing oncologists with a comprehensive molecular profile of a patient’s cancer to inform personalized treatment strategies. GPS Cancer testing is conducted in the CLIA-certified, CAP-accredited laboratory of NantOmics, and is a key enabler for Cancer Breakthroughs 2020, the world’s most comprehensive cancer collaborative initiative seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. For more information, visit and

About NantHealth

NantHealth, a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth‘s unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, NantHealth has developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time. For more information please visit and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

Media Contact

Jen Hodson


Direct: 562-397-3639